Pfizer (PFE) Q2 2026 Earnings: $15.03B Revenue Beat and Newer Drug Growth Lift Shares 1.52%
AI Market Summary
Pfizer's Q2 2026 results beat on revenue ($15.03B) and adjusted EPS ($0.77), and management lifted the FY2026 revenue floor and midpoint while reiterating EPS guidance. Shares rose 1.52% as investors looked through a GAAP loss driven by $4.3B non-cash impairments. The key near-term focus is whether newer oncology and specialty drugs can offset sharp COVID-product declines and upcoming patent pressures.
Impact level
● Medium
Affected assets
NCSKPFE2USD/USDT-0.51%
AI Insight · NCSKPFE2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Pfizer reported Q2 2026 results led by $15.03B Revenue and $0.77 Adjusted EPS, and PFE shares moved +1.52% in the completed reaction session. The analysis explains the earnings mix, financial outlook and three-month technical levels.
